GENFIT Reports Robust Progress Under Liquidity Agreement
GENFIT Updates on Liquidity Contract Progress
GENFIT (Nasdaq and Euronext: GNFT), a dedicated biopharmaceutical company, focuses on patients suffering from rare liver diseases. Today, they reported the progress of their liquidity contract with Crédit Industriel et Commercial.
Current Liquidity Resources
As of the latest assessment, the liquidity account reflected the following:
- 207,500 shares
- €353,960.14
Trading Performance
Throughout the last half of the specified year, trading was significant:
- Buy Side: 2,075,591 shares totaling €8,893,798.52.
- Sell Side: 1,999,091 shares totaling €8,546,873.15.
Trade Count Breakdown
The trades were reported as follows:
- Buy Side: 2,752 trades
- Sell Side: 2,582 trades
Initial Resources Overview
Upon signing the liquidity contract, the account originally contained:
- 27,911 shares
- €769,849.43
About GENFIT
GENFIT is at the forefront of biopharmaceutical research and development, primarily targeting liver diseases. With over two decades of experience, they have cultivated a diverse and rapidly evolving R&D portfolio. Their primary focus includes therapies for Acute-on-Chronic Liver Failure (ACLF), with five assets actively in development: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE, each leveraging different mechanisms of action.
Additionally, GENFIT’s developments extend to serious diseases such as cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemia (OA). Their commitment to advancing health solutions has been exemplified through the accelerated approval of elafibranor, marketed as Iqirvo® in the U.S by Ipsen for Primary Biliary Cholangitis (PBC).
Expertise and Achievements
With a strong pipeline and a commitment to innovation, GENFIT's expertise spans from molecule development through to pre-commercialization. The company also has a diagnostics arm, including NIS2+® targeting metabolic dysfunction-associated steatohepatitis (MASH) and TS-01 for monitoring blood ammonia levels. Headquartered in France with offices in Paris, Zurich, and Cambridge, MA, GENFIT continues to expand its reach and impact in the biopharmaceutical industry.
Communication Channels
For additional information, interested parties can reach out to GENFIT via their investor relations:
- Contact Number: +33 3 2016 4000
- Email: investors@genfit.com
Frequently Asked Questions
1. What is the primary focus of GENFIT?
GENFIT primarily focuses on biopharmaceutical development aimed at treating rare liver diseases.
2. What recent liquidity updates did GENFIT provide?
GENFIT reported liquidity resources totaling 207,500 shares and €353,960.14.
3. Which medications are in GENFIT's pipeline?
GENFIT’s pipeline includes five ACLF assets: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE.
4. How can investors contact GENFIT for inquiries?
Investors can reach out to GENFIT at +33 3 2016 4000 or via email at investors@genfit.com.
5. What is the significance of elafibranor for GENFIT?
Elafibranor is a significant therapy for GENFIT, receiving accelerated approval for the treatment of Primary Biliary Cholangitis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
